You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In PLOS this week: recombination density-based method for calibrating human mutation rates, pathogen-typing approach using solid-state nanopores, and more.
Adjusted revenues grew 2 percent year over year, highlighted by growth in the company's QuantiFERON-TB test and an expansion of pharma partnerships for companion diagnostics.
In PNAS this week: genome and transcriptome of the Asian tiger mosquito, TB diversity and virulence in Inuit populations, and more.
Genome sequence data revealed a single Mycobacterium tuberculosis introduction to northern Quebec in the early 20th century, without a subsequent rise in virulence.
The database of genotype, phenotype, and clinical data from multi-drug resistant TB cases may support improved diagnostic development and clinical decision making.
The test runs on the firm's m2000 PCR platform and is the first on the market to assess resistance to both rifampin and isoniazid.
Genome sequencing is a new tool in the fight against drug-resistant bacteria, writes Lara Marks at The Conversation.
The funding comes as part of the agency's Advanced Molecular Detection initiative, which is using the technologies to help address infectious disease outbreaks.
In PLOS this week: mitochondrial DNA dynamics, tuberculosis transmission patterns in Malawi, and more.
The project aims to use omics and systems biology approaches to characterize strains of tuberculosis with an eye toward identifying therapeutic targets.
According to ScienceInsider, the US National Academies of Science, Engineering, and Medicine is planning a study of racism in academic research.
The Washington Post writes that the approval in the US of a SARS-CoV-2 vaccine will be up to Peter Marks, a career official at the Food and Drug Administration.
NPR reports the US loan to Eastman Kodak to boost domestic pharmaceutical production is on pause following insider trading allegations.
In Cell this week: blood immune cell changes in COVID-19 patients and spatial transcriptomics in Alzheimer's disease.